J Am Coll Cardiol. 2014;63(17):1758-1760. - - PowerPoint PPT Presentation

▶
j am coll cardiol 2014 63 17 1758 1760 doi 10 1016 j jacc
SMART_READER_LITE
LIVE PREVIEW

J Am Coll Cardiol. 2014;63(17):1758-1760. - - PowerPoint PPT Presentation

Feb 12, 2023 258 likes •559 views

J Am Coll Cardiol. 2014;63(17):1758-1760. doi:10.1016/j.jacc.2014.02.531 The Journal of Heart and Lung Transplantation 2017 36, 1037-1046DOI: (10.1016/j.healun.2017.07.019) The Journal of Heart and Lung Transplantation 2017 36, 1037-1046DOI:

slide-1
SLIDE 1
slide-2
SLIDE 2
slide-3
SLIDE 3

J Am Coll Cardiol. 2014;63(17):1758-1760. doi:10.1016/j.jacc.2014.02.531

slide-4
SLIDE 4
slide-5
SLIDE 5

The Journal of Heart and Lung Transplantation 2017 36, 1037-1046DOI: (10.1016/j.healun.2017.07.019)

slide-6
SLIDE 6
slide-7
SLIDE 7

The Journal of Heart and Lung Transplantation 2017 36, 1037-1046DOI: (10.1016/j.healun.2017.07.019)

slide-8
SLIDE 8

The Journal of Heart and Lung Transplantation 2017 36, 1037-1046DOI: (10.1016/j.healun.2017.07.019)

slide-9
SLIDE 9

The Journal of Heart and Lung Transplantation 2017 36, 1037-1046DOI: (10.1016/j.healun.2017.07.019)

slide-10
SLIDE 10

OPTN/SRTR 2016 Annual Data Report: Heart, Volume: 18, Issue: S1, Pages: 291-362, First published: 02 January 2018, DOI: (10.1111/ajt.14561)

slide-11
SLIDE 11
slide-12
SLIDE 12

Percentage of adults who underwent deceased donor heart transplant within 1 year of listing in 2015 by DSA.

OPTN/SRTR 2016 Annual Data Report: Heart, Volume: 18, Issue: S1, Pages: 291-362, First published: 02 January 2018, DOI: (10.1111/ajt.14561)

Pretransplant mortality rates among adults waitlisted for heart transplant in 2015‐2016, by DSA. Mortality rates are computed as the number of deaths per 100 patient‐years of waiting in the given year.

Why do these discrepancies exist?

slide-13
SLIDE 13
slide-14
SLIDE 14

No more 1A, 1B, Status 2!

slide-15
SLIDE 15

Heart Geographic Distribution

Local 500 1000 1500 2500 > 2500

New Heart Allocation policy starting October 18th, 2018 1) Change from 3 to 6 status groups 2) Expands “local” geographic distribution to a 500 mile radius from the donor 3) Goal is to decrease waitlist mortality and to have more equitable sharing of organs

slide-16
SLIDE 16

The Journal of Heart and Lung Transplantation 2018 37, 763-769DOI: (10.1016/j.healun.2018.01.1293)

Major advances in treatment of Hepatitis C Virus Transplant Nephrology has embraced HCV + donors with robust results Evolving area of investigation of other solid

  • rgan transplants to potentially expand the

donor pool. Partially related to opioid crisis

slide-17
SLIDE 17
slide-18
SLIDE 18
slide-19
SLIDE 19

The Journal of Heart and Lung Transplantation 2017 36, 1047-1059DOI: (10.1016/j.healun.2017.07.016)

slide-20
SLIDE 20

The Journal of Heart and Lung Transplantation 2017 36, 1047-1059DOI: (10.1016/j.healun.2017.07.016)

slide-21
SLIDE 21

The Journal of Heart and Lung Transplantation 2017 36, 1047-1059DOI: (10.1016/j.healun.2017.07.016)

‐Declining volumes since 1989 (225)

to 2015 (38) ‐Most common indication is Pulmonary Hypertension ( 66%) of cases ‐ High short term mortality. ‐ Median survival is 10.3 years if pt survives the first year post transplant (conditional survival) ‐ Costs of $2.6 Million/transplant ‐ Most recipients are < 50yo

slide-22
SLIDE 22
  • Overall: 1.4M

890K

  • Overall: 860K/1.19M

475K/680K

Combined Heart Kidney $2.5 million, Combined Heart Lung $2.6 million

slide-23
SLIDE 23
slide-24
SLIDE 24

Patel, N, et al. J Am Coll Cardiol HF 2018;6:424‐32

slide-25
SLIDE 25

Patel, N, et al. J Am Coll Cardiol HF 2018;6:424‐32

slide-26
SLIDE 26
slide-27
SLIDE 27
slide-28
SLIDE 28
slide-29
SLIDE 29